biotech · Advanced Solid Tumors · Tumor, Solid · EIKN
Eikon Therapeutics drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 13 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Eikon Therapeutics drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L02) compound in Eikon Therapeutics's portfolio. Molecular target: Androgen receptor.
US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
Development asset linked to Eikon Therapeutics in public FDA and regional records.
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
Development asset linked to Eikon Therapeutics in public FDA and regional records.
Development asset linked to Eikon Therapeutics in public FDA and regional records.
US regulatory status: approved. Molecular target: Tubulin.
US regulatory status: approved. Molecular target: Programmed cell death protein 1.
Development asset linked to Eikon Therapeutics in public FDA and regional records.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
Development asset linked to Eikon Therapeutics in public FDA and regional records.
Development asset linked to Eikon Therapeutics in public FDA and regional records.
Development asset linked to Eikon Therapeutics in public FDA and regional records.